ArticleDiscover oncology2025
Obese patients with malignant tumor: a case series and literature review.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Evaluating the prognostic value of body mass index in diffuse large B-cell lymphoma: a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPharmacological treatment of malignant tumors in obese patients has been reported from several perspectives. Physiological changes may affect the kinetics of anticancer drugs (e.g., lipophilicity, distribution volume, and metabolism), consequently affecting their efficacy and safety profile. However, specific guidelines for antineoplastic agent dose adjustment according to body weight, mainly due to the under-representation of obese patients in clinical trials, are currently lacking. Moreover, considering that certain tumor development is associated with obesity, the clinical management of obese patients is often complex. We herein report the antitumor treatment options of three obese patients with malignant tumors and review relevant literature to analyze the dosage of antitumor drugs in this setting. This study aims to provide additional data for the clinical treatment of obese patients with malignant tumors. CASE PRESENTATION: In Case 1, carboplatin was administered at a fixed dose, mainly because of neurotoxicity risk. A maximum creatinine clearance rate (glomerular filtration rate) of 125 mL/min is recommended to prevent carboplatin overdose and toxicity. The maximum carboplatin dose was calculated using the following formula: maximum dose = area under the curve (AUC) × (125 + 25). Methotrexate dose was calculated based on the actual body weight of Cases 2 and 3. While receiving methotrexate, the blood drug concentration was within the reference range (24-h reference concentration ≤ 10 μmol/L), and no serious adverse reactions occurred. As seen in the three cases, considering the particularity of some drugs, for example, more than 90% of carboplatin is excreted through the kidney, carboplatin should be administered at a fixed dose, while other chemotherapy drugs can be administered according to the actual body weight as much as possible according to the patient's condition.
conclusionsThe toxicity of chemotherapy has traditionally been assessed based on the actual body weight of obese and non-obese patients. In clinical practice, overweight and obese cancer patients often receive reduced doses of chemotherapy drugs. According to the guidelines set by the American Society of Clinical Oncology, the positive association between the use of chemotherapy and treatment-related toxicity in obese patients lacks evidence. After comprehensive consideration of complications, chemotherapy dose should be determined based on the body surface area(BSA) calculated based on actual body weight, rather than estimated or idealized body weight.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.